Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
-
2121
-
2122
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2123
-
2124
-
2125
-
2126
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2127
-
2128
-
2129
-
2130
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2131
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2132
-
2133
-
2134
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2135
-
2136
-
2137
-
2138
-
2139
-
2140